Literature DB >> 17407040

The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus.

Fred C Tenover1, Robert C Moellering.   

Abstract

The Clinical and Laboratory Standards Institute (formerly, the NCCLS) established the susceptibility and resistance breakpoints for minimal inhibitory concentration (MIC) and disk diffusion testing of vancomycin against isolates of Staphylococcus aureus > 20 years ago. The disk diffusion breakpoints were modified in 1998 when it was recognized that vancomycin-intermediate S. aureus strains were not detected by this method. In 2006, the vancomycin MIC breakpoints for S. aureus were lowered (from < or = 4 microg/mL to < or = 2 microg/mL for "susceptible," from 8-16 microg/mL to 4-8 microg/mL for "intermediate," and from > or = 32 microg/mL to > or = 16 microg/mL for "resistant") to increase detection of heterogeneously resistant isolates of S. aureus. This decision reflected a growing amount of microbiological and clinical data indicating that isolates of S. aureus are less likely to respond to vancomycin therapy when the vancomycin MICs are > or = 4 microg/mL.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17407040     DOI: 10.1086/513203

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  119 in total

1.  A report on the first case of vancomycin-intermediate Staphylococcus aureus (VISA) in Hawai'i.

Authors:  Suttirak Chaiwongkarjohn; Pornpoj Pramyothin; Nuntra Suwantarat; Matthew J Bankowski; Terrie Koyamatsu; Steven E Seifried; Erlaine F Bello
Journal:  Hawaii Med J       Date:  2011-11

2.  Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate Staphylococcus aureus in bloodstream isolates.

Authors:  Sebastian J van Hal; Michael C Wehrhahn; Thelma Barbagiannakos; Joanne Mercer; Dehua Chen; David L Paterson; Iain B Gosbell
Journal:  J Clin Microbiol       Date:  2011-01-26       Impact factor: 5.948

3.  Meta-analysis of randomized controlled trials of vancomycin for the treatment of patients with gram-positive infections: focus on the study design.

Authors:  Konstantinos Z Vardakas; Michael N Mavros; Nikolaos Roussos; Matthew E Falagas
Journal:  Mayo Clin Proc       Date:  2012-04       Impact factor: 7.616

Review 4.  Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates.

Authors:  Sebastiaan J van Hal; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

Review 5.  Evolving resistance among Gram-positive pathogens.

Authors:  Jose M Munita; Arnold S Bayer; Cesar A Arias
Journal:  Clin Infect Dis       Date:  2015-09-15       Impact factor: 9.079

6.  Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy.

Authors:  Fred C Tenover; Scott W Sinner; Robert E Segal; Vanthida Huang; Shandline S Alexandre; John E McGowan; Melvin P Weinstein
Journal:  Int J Antimicrob Agents       Date:  2009-02-23       Impact factor: 5.283

Review 7.  Exploring innate glycopeptide resistance mechanisms in Staphylococcus aureus.

Authors:  Adriana Renzoni; William L Kelley; Pierre Vaudaux; Ambrose L Cheung; Daniel P Lew
Journal:  Trends Microbiol       Date:  2009-12-11       Impact factor: 17.079

8.  Factors influencing time to vancomycin-induced clearance of nonendocarditis methicillin-resistant Staphylococcus aureus bacteremia: role of platelet microbicidal protein killing and agr genotypes.

Authors:  Pamela A Moise; Alan Forrest; Arnold S Bayer; Yan Q Xiong; Michael R Yeaman; George Sakoulas
Journal:  J Infect Dis       Date:  2010-01-15       Impact factor: 5.226

Review 9.  Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infections.

Authors:  Christopher Giuliano; Christopher Giulano; Krystal K Haase; Ronald Hall
Journal:  Expert Rev Anti Infect Ther       Date:  2010-01       Impact factor: 5.091

10.  Novel screening agar for detection of vancomycin-nonsusceptible Staphylococcus aureus.

Authors:  Carey-Ann D Burnham; Carol J Weber; W Michael Dunne
Journal:  J Clin Microbiol       Date:  2010-01-20       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.